CA2528095C - Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof - Google Patents

Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof Download PDF

Info

Publication number
CA2528095C
CA2528095C CA2528095A CA2528095A CA2528095C CA 2528095 C CA2528095 C CA 2528095C CA 2528095 A CA2528095 A CA 2528095A CA 2528095 A CA2528095 A CA 2528095A CA 2528095 C CA2528095 C CA 2528095C
Authority
CA
Canada
Prior art keywords
methods
compositions
making
pathogenic microorganisms
inactivating pathogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2528095A
Other languages
French (fr)
Other versions
CA2528095A1 (en
Inventor
James R. Baker
Ted C. Annis
Tarek Hamouda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanobio Corp
Original Assignee
Nanobio Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobio Corp filed Critical Nanobio Corp
Publication of CA2528095A1 publication Critical patent/CA2528095A1/en
Application granted granted Critical
Publication of CA2528095C publication Critical patent/CA2528095C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Nanoemulsion compositions with low toxicity that demonstrate broad spectrum inactivation of microorganisms or prevention of diseases are described. The nanoemulsions contain an aqueous phase, an oil phase comprising an oil and an organic solvent, and one or more surfactants. Methods of making nanoemulsions and inactivating pathogenic microorganisms are also provided.
CA2528095A 2003-06-04 2004-06-03 Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof Expired - Lifetime CA2528095C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45763303P 2003-06-04 2003-06-04
US60/475,633 2003-06-04
PCT/US2004/017417 WO2005027872A2 (en) 2003-06-04 2004-06-03 Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof

Publications (2)

Publication Number Publication Date
CA2528095A1 CA2528095A1 (en) 2005-03-31
CA2528095C true CA2528095C (en) 2014-10-14

Family

ID=34375188

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2528095A Expired - Lifetime CA2528095C (en) 2003-06-04 2004-06-03 Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof

Country Status (4)

Country Link
EP (1) EP1633322A2 (en)
AU (1) AU2004273779B2 (en)
CA (1) CA2528095C (en)
WO (1) WO2005027872A2 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763663B2 (en) 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US8067371B2 (en) 2003-05-09 2011-11-29 The Trustees Of Columbia University In The City Of New York RAGE G82S-related methods and compositions for treating inflammatory disorders
JP5368793B2 (en) * 2005-07-18 2013-12-18 ユニバーシティ オブ マサチューセッツ ロウエル Compositions and methods for making and using nanoemulsions
AU2016244292A1 (en) * 2005-07-18 2016-11-03 University Of Massachusetts Lowell Compositions and methods for making and using nanoemulsions
CA2618974C (en) * 2005-08-09 2014-01-28 Nanobio Corporation Nanoemulsion compositions having anti-inflammatory activity
TR201901443T4 (en) 2005-12-01 2019-02-21 Univ Massachusetts Lowell Botulinum nanoemulsions.
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
EP2010149A1 (en) * 2006-04-07 2009-01-07 Novavax, Inc. Nanostructured compositions having antibacterial, anti-fungal, anti-yeast, and/or anti-viral properties
WO2007120860A2 (en) * 2006-04-13 2007-10-25 The Regents Of The University Of Michigan Nanoemulsion vaccines
US9839685B2 (en) 2006-04-13 2017-12-12 The Regents Of The University Of Michigan Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
US10138279B2 (en) 2006-04-13 2018-11-27 Regents Of The University Of Michigan Compositions and methods for Bacillus anthracis vaccination
FR2907012B1 (en) * 2006-10-12 2012-09-21 Galderma Sa DERMATOLOGICAL COMPOSITION COMPRISING AVERMECTIN NANOCAPSULES, PROCESS FOR PREPARING THE SAME AND USE THEREOF
EP2494958A1 (en) 2006-12-01 2012-09-05 Anterios, Inc. Amphiphilic Entity Nanoparticles
BRPI0719732A2 (en) 2006-12-01 2017-05-16 Anterios Inc peptide nanoparticles and uses thereof
EP1938801A1 (en) * 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
DE102007007698A1 (en) * 2007-02-09 2008-08-21 Exner, Heinrich, Dr. Use of a highly emulsified silicone oil emulsion (HSE) for the manufacture of a medicament
ES2660906T3 (en) 2007-05-31 2018-03-26 Anterios, Inc. Nucleic acid nanoparticles and uses thereof
BRPI0705564B8 (en) * 2007-10-10 2021-05-25 Embrapa Pesquisa Agropecuaria continuous liquid crystal type system containing co-solvents carrying sparingly soluble substances in water, its process of obtaining and its uses
EP3023107A1 (en) 2008-04-21 2016-05-25 Nanobio Corporation Nanoemulsion influenza vaccine
WO2009132343A1 (en) * 2008-04-25 2009-10-29 Nanobio Corporation Nanoemulsions for treating onchomycosis
WO2009132342A1 (en) * 2008-04-25 2009-10-29 Nanobio Corporation Nanoemulsions for treating fungal, yeast and mold infections
WO2009143524A2 (en) 2008-05-23 2009-11-26 The Regents Of The University Of Michigan Nanoemulsion vaccines
WO2009158687A1 (en) * 2008-06-26 2009-12-30 Anterios, Inc. Dermal delivery
CA2738245A1 (en) 2008-09-26 2010-04-01 Nanobio Corporation Nanoemulsion therapeutic compositions and methods of using the same
RU2526138C2 (en) * 2008-12-31 2014-08-20 Сунев Фарма Солюшн Лимитед Topical herbal formulation for treating acne and skin disorders
WO2010140170A1 (en) * 2009-06-05 2010-12-09 Sunev Pharma Solution Limited Topical micro-emulsions for the treatment of rheumatic disorders
CN102740832B (en) † 2009-12-03 2016-01-13 诺华股份有限公司 With regard to Micro Fluid arrangement reciprocal action and back pressure chamber
DE102009056871A1 (en) 2009-12-03 2011-06-22 Novartis AG, 4056 Vaccine adjuvants and improved methods of making the same
AU2013213678B2 (en) * 2009-12-03 2016-06-23 Novartis Ag Arranging interaction and back pressure chambers for microfluidization
CA2782511C (en) 2009-12-03 2013-11-12 Novartis Ag Circulation of components during homogenization of emulsions
DE102009056883B4 (en) 2009-12-03 2012-08-16 Novartis Ag Vaccine adjuvants and improved methods of making the same
CL2012001399A1 (en) 2009-12-03 2013-03-08 Novartis Ag Method to manufacture adjuvant for vaccine (oil / water emulsion with squalene, polysorbate 80 and sorbitan trioleate), which comprises (i) forming the first emulsion in a homogenizer from one container to another to form a second emulsion, (ii) and microfluidizing the first emulsion to form second emulsion.
EA025622B1 (en) 2009-12-03 2017-01-30 Новартис Аг Method for manufacture of a squalene-containing oil-in-water emulsion
DE102009056884B4 (en) 2009-12-03 2021-03-18 Novartis Ag Vaccine Adjuvants and Improved Methods for Making Same
DE202010004750U1 (en) * 2010-04-09 2011-10-11 Biofrontera Bioscience Gmbh Pharmaceutical and / or cosmetic composition for the treatment of the skin
WO2013163176A1 (en) 2012-04-23 2013-10-31 Allertein Therapeutics, Llc Nanoparticles for treatment of allergy
WO2014206857A1 (en) * 2013-06-28 2014-12-31 Universitat Autonoma De Barcelona Oil-in-water formulations of mycobacterium and uses thereof
WO2015143444A1 (en) * 2014-03-21 2015-09-24 University Of Florida Research Foundation, Inc. Use of aldehydes formulated with nanoparticles and/or nanoemulsions to enhance disease resistance of plants to liberibacters
CN104274405A (en) * 2014-10-21 2015-01-14 河南牧翔动物药业有限公司 Oil-in-water type compound ceftiofur nanoemulsion antimicrobial medicament
US10413508B2 (en) 2015-02-06 2019-09-17 R. P. Scherer Technologies, Llc Preparation of an oil-in-water emulsion for polymer stabilized pharmaceutical formulations
US20190185864A1 (en) 2016-08-23 2019-06-20 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
KR102487144B1 (en) 2016-11-21 2023-01-12 에이리온 테라퓨틱스, 인코포레이티드 Transdermal delivery of large substances
CN106924730B (en) * 2017-02-14 2019-11-08 商丘美兰生物工程有限公司 Porcine pseudorabies virus Aloe Vera Gel nano emulsion adjuvant inactivated vaccine and preparation method thereof
EP3743038B1 (en) 2018-01-23 2021-10-13 Unilever IP Holdings B.V. Process for making transparent nanoemulsions comprising lauric oil
EP3743037B1 (en) 2018-01-23 2021-10-13 Unilever IP Holdings B.V. Transparent nanoemulsions comprising lauric oil
EP4114958A1 (en) 2020-02-21 2023-01-11 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
CN113662006B (en) * 2021-06-30 2022-05-20 南京凯创协同纳米技术有限公司 Preparation method of micro-nano zinc capable of killing bacteria and inactivating viruses
WO2024005601A1 (en) * 2022-06-30 2024-01-04 씨제이제일제당(주) Medical composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2912426B2 (en) * 1990-06-15 1999-06-28 鐘紡株式会社 Micronized emulsion composition
US6506803B1 (en) * 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
PT1345597E (en) * 2000-12-27 2007-10-29 Ares Trading Sa Amphiphilic lipid nanoparticles for peptide and/or protein incorporation
AU2002367976B2 (en) * 2001-06-05 2007-06-21 The Regents Of The University Of Michigan Nanoemulsion vaccines

Also Published As

Publication number Publication date
AU2004273779B2 (en) 2009-10-22
AU2004273779A2 (en) 2005-03-31
WO2005027872A3 (en) 2006-03-09
CA2528095A1 (en) 2005-03-31
AU2004273779A1 (en) 2005-03-31
WO2005027872A2 (en) 2005-03-31
EP1633322A2 (en) 2006-03-15

Similar Documents

Publication Publication Date Title
CA2528095C (en) Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof
WO2008051186A3 (en) Nanoemulsion containing compositions having ant i -inflammatory activity
EP2949644A3 (en) Substituted tetracycline compounds
WO2004098494A3 (en) Compounds, compositions, and methods
WO2004103960A3 (en) Compounds and uses thereof
WO2004014893A3 (en) Antimicrobial aza-bicyclic derivates, their compositions and uses
WO2005066151A3 (en) Histone deacetylase inhibitors
EP2345637A3 (en) 3, 10, and 12a substituted tetracycline compounds
WO2007044032A3 (en) Compositions having a high antiviral and antibacterial efficacy
WO2006099192A3 (en) Stable organic peroxide compositions
EP2518079A3 (en) HCV/HIV inhibitors and their uses
WO2007005471A3 (en) Stable organic peroxide compositions
WO2006114186A3 (en) Water-in-oil suspoemulsions
WO2006105889A3 (en) Synergistic fungicidal active substance combinations
WO2006097617A3 (en) Novel dihydropyrimidine derivatives and their use as anti-cancer agents
WO2005007103A3 (en) Use of parthenolide derivatives as antileukemic and cytotoxic agents
WO2008048121A3 (en) Macrocyclic cysteine protease inhibitors and compositions thereof
WO2006133006A3 (en) 1-methyl-1h-pyrazole-4-carboxamides useful as cancer chemotherapeutic agents
WO2002080855A3 (en) Methods and compounds for decreasing cell toxicity or death
WO2004091513A3 (en) 9-aminomethyl substituted minocycline compounds
WO2004034961A3 (en) Antimicrobial agents and uses thereof
WO2004098522A3 (en) Gemini vitamin d3 compounds and methods of use thereof
WO2006077189A3 (en) 6-azo-5,5'-dihydroxy-7,7'-disulfo-2,2'-dinaphthylamine derivatives
WO2006132662A3 (en) Self assembled nanostructures and methods for preparing the same
WO2006027344A3 (en) 3-oxa-10-aza-phenanthrenes as pde4 or pde3/4 inhibitors

Legal Events

Date Code Title Description
EEER Examination request